Preferred Label : lebrikizumab;

MeSH note : anti-interleukin-13 MAb for treatment of asthma;

MeSH hyponym : MILR-1444A; PRO-301444;

Is substance : O;

UNII : U9JLP7V031;

Détails


Consulter ci-dessous une sélection des principales ressources :

Vous pouvez consulter :


https://www.ema.europa.eu/en/medicines/human/EPAR/ebglyss
2024
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
lebrikizumab
lebrikizumab
lebrikizumab
drug approval
europe
dermatitis, atopic
adult
child
adolescent
injections, subcutaneous
risk management
product surveillance, postmarketing
aged
pregnancy
breast feeding
drug interactions
Interleukin-13
drug evaluation, preclinical

---
https://www.has-sante.fr/jcms/p_3542722/fr/ebglyss-lebrikizumab-dermatite-atopique
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
lebrikizumab
adult
adolescent
antibodies, monoclonal
evaluation of the transparency committee
lebrikizumab
dermatitis, atopic

---
https://www.has-sante.fr/jcms/p_3522389/fr/ebglyss-lebrikizumab-dermatite-atopique
2024
false
false
false
France
lebrikizumab
treatment outcome
insurance, health, reimbursement
adult
antibodies, monoclonal
evaluation of the transparency committee
lebrikizumab
dermatitis, atopic

---
Nous contacter.
27/07/2025


[Accueil] [Haut de page]

© CHU de Rouen. Toute utilisation partielle ou totale de ce document doit mentionner la source.